The clinical complications caused by different CAR-T in MM are similar to those led by CD19-targeted CAR-T in ALL and DLBCL (84, 145, 146), including cytokine release syndrome (CRS) and neurotoxicity (NTX), and hematologic cytopenia, which might limit the wide application of CAR-T cell therapy in MM. Here, CD19 is linked to Miyoshi myopathy.